The U.S. Food and Drug Administration expanded its approval of Moderna's respiratory syncytial virus (RSV) vaccine on Thursday to include adults under the age of 60 at increased risk of the disease.

Moderna filed for FDA approval on data from a late-stage trial that showed its vaccine was 83.7% effective at preventing at least two symptoms of RSV, such as cough and fever.

The Moderna RSV vaccine, which will be marketed under the name mResvia, was approved for adults 60 and older. It is made using the same messenger RNA platform as Moderna’s other licensed product ...

The US Food and Drug Administration has approved another vaccine that can help protect older people from respiratory syncytial virus, known as RSV. The shot, made by Moderna and sold under the ...

The FDA expanded the approval of the GSK vaccine in June to include adults ages 50 to 59 at risk of RSV-LRTD due to underlying conditions. The Moderna vaccine is approved for people ages 60 and ...

The US Food and Drug Administration (FDA) approved mRESVIA (mRNA-1345, Moderna), a vaccine for respiratory syncytial virus (RSV). The mRNA vaccine is approved for adults aged 60 years or older to ...

The FDA approved the first-ever mRNA-1345 vaccine (mRESVIA) for respiratory syncytial virus (RSV) for people ages 60 and older to protect against lower respiratory tract disease, Moderna announced ...

The approval of Moderna's shot is based on a late-stage trial on older adults, who are more vulnerable to severe cases of RSV. The virus kills between 6,000 and 10,000 seniors every year and ...

New: The FDA has expanded the approval for GSK’s vaccine to protect against respiratory syncytial virus, or RSV, authorizing its use for at-risk adults as young as 50.

Moderna’s RSV vaccine is based on mRNA technology, which some of the new members have expressed skepticism about, especially in relation to COVID-19 vaccines. Despite availability, RSV ...